Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;269(7):3682-3689.
doi: 10.1007/s00415-022-10990-7. Epub 2022 Feb 11.

Long-term follow-up of respiratory function in facioscapulohumeral muscular dystrophy

Sjan Teeselink  1 , Sanne C C Vincenten  2 , Nicol C Voermans  2 , Jan T Groothuis  3 , Jonne Doorduin  2 , Peter J Wijkstra  4   5 , Corinne G C Horlings  6 , Baziel G M van Engelen  2 , Karlien Mul  2
Affiliations

Long-term follow-up of respiratory function in facioscapulohumeral muscular dystrophy

Sjan Teeselink et al. J Neurol. 2022 Jul.

Abstract

Objective: To evaluate the 5-year change in respiratory function in patients with facioscapulohumeral muscular dystrophy (FSHD).

Methods: Genetically confirmed patients with FSHD aged ≥ 18 years were examined twice over five years. Forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were measured using hand-held spirometry with a face mask. Several clinical outcome measures were correlated to respiratory function.

Results: Ninety-two patients were included (57% male, age 18-75 years). At baseline, the spirometry outcomes of 41 patients showed a restrictive ventilatory pattern (FVC < 80% and FEV1/FVC ≥ 70% of predicted) and of 48 patients at follow-up. The mean FVC decreased from baseline to follow-up from 79.0 to 76.7% predicted (p = 0.021). This decrease was driven by a subgroup of 15 patients who had a deterioration of FVC of > 10% predicted. The subgroup of 15 patients was more severely affected at baseline (p = 0.002 for FSHD clinical score and 0.007 for Ricci score). They developed more frequently spinal and thorax deformities (p < 0.001 for kyphoscoliosis and 0.012 for pectus excavatum) and had a larger decline in axial muscle function (p = 0.020). Only weak correlations were found between the change in FVC% predicted and the change in clinical scores between baseline and follow-up.

Interpretation: Respiratory function remained stable in most patients with FSHD, but a subgroup of patients showed a pronounced deterioration. They showed more severe muscle weakness including the leg muscles at baseline (Ricci score ≥ 6), had spinal and thorax deformities and a relatively fast decline in axial muscle function at follow-up.

Keywords: Facioscapulohumeral muscular dystrophy; Long-term follow-up; Respiratory function; Spirometry.

PubMed Disclaimer

Conflict of interest statement

ST, SV, CH, JD, PW, KM and NV have no relevant financial or non-financial interests to disclose. JG reports grants from Prinses Beatrix Spierfonds and Fulcrum Therapeutics. BvE reports grants from Prinses Beatrix Spierfonds, Dutch FSHD Foundation and charitable foundation Spieren voor Spieren and consultancy for Fulcrum Therapeutics, Facio Therapies and Arrowhead Pharmaceuticals.

Figures

Fig. 1
Fig. 1
Histogram of change in FVC% of predicted between baseline and follow-up. Mean change in FVC% predicted was 2.3 (SD 9.4). Change values were calculated by subtracting the follow-up value from the baseline value
See this image and copyright information in PMC

References

    1. Deenen JC, Arnts H, van der Maarel SM, et al. Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology. 2014;83(12):1056–1059. doi: 10.1212/WNL.0000000000000797. - DOI - PMC - PubMed
    1. Mul K, Lassche S, Voermans NC, Padberg GW, Horlings CG, van Engelen BG. What's in a name? The clinical features of facioscapulohumeral muscular dystrophy. Pract Neurol. 2016;16(3):201–207. doi: 10.1136/practneurol-2015-001353. - DOI - PubMed
    1. Wohlgemuth M, van der Kooi EL, van Kesteren RG, van der Maarel SM, Padberg GW. Ventilatory support in facioscapulohumeral muscular dystrophy. Neurology. 2004;63(1):176–178. doi: 10.1212/01.wnl.0000133126.86377.e8. - DOI - PubMed
    1. Scully MA, Eichinger KJ, Donlin-Smith CM, Tawil R, Statland JM. Restrictive lung involvement in facioscapulohumeral muscular dystrophy. Muscle Nerve. 2014;50(5):739–743. doi: 10.1002/mus.24218. - DOI - PMC - PubMed
    1. Moreira S, Wood L, Smith D, et al. Respiratory involvement in ambulant and non-ambulant patients with facioscapulohumeral muscular dystrophy. J Neurol. 2017;264(6):1271–1280. doi: 10.1007/s00415-017-8525-9. - DOI - PMC - PubMed